Response to the Center for Medicare & Medicaid Services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: Data from the OMNI study

Medicine & Life Sciences

• Centers for Medicare and Medicaid Services (U.S.) 100%
• Implantable Defibrillators 89%
• Primary Prevention 80%
• Cardiac Resynchronization Therapy 52%
• Defibrillators 51%
• Heart Failure 50%
• Dilated Cardiomyopathy 47%
• Stroke Volume 39%
• Tachycardia 25%
• Heart 16%
• Observational Studies 13%
• Mortality 8%
• Coronary Disease 7%
• Therapeutics 5%
• Prospective Studies 5%
• Survival 4%